Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) insider Victoria Hull sold 2,777 shares of the company’s stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of GBX 1,800 ($22.91), for a total transaction of £49,986 ($63,627.80).
Hikma Pharmaceuticals Stock Up 2.6 %
Shares of LON HIK traded up GBX 47 ($0.60) during mid-day trading on Tuesday, reaching GBX 1,841 ($23.43). The company had a trading volume of 552,782 shares, compared to its average volume of 1,700,715. Hikma Pharmaceuticals PLC has a 52-week low of GBX 1,750 ($22.28) and a 52-week high of GBX 2,360 ($30.04). The stock has a market cap of £5.11 billion, a P/E ratio of 18.07, a PEG ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm has a 50 day simple moving average of GBX 2,148.46 and a two-hundred day simple moving average of GBX 2,016.29.
Hikma Pharmaceuticals Increases Dividend
The firm also recently announced a dividend, which will be paid on Thursday, May 1st. Stockholders of record on Thursday, March 20th will be issued a $0.48 dividend. This represents a dividend yield of 1.8%. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.32. The ex-dividend date of this dividend is Thursday, March 20th. Hikma Pharmaceuticals’s dividend payout ratio is presently 60.84%.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on HIK
Hikma Pharmaceuticals Company Profile
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- How to Choose Top Rated Stocks
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- Investing in Travel Stocks Benefits
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.